Retrospective analysis of PD-L2 in the tumors from the Phase III KEYNOTE-756 [14] and Checkmate-7FL [15] clinical trials may help explain the improved rates of pathological complete response to PD-1i in ER+ BC. Here, PDCD1LG2 is linked to breast cancer.